
Fermenta Biotech Q3 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Human Vitamin D3 demand is expected to stabilize at levels higher than pre-pandemic, supported by increasing awareness of its immunity benefits.
- Animal feed Vitamin D3 volumes showed a 145% increase in Q3 FY22 vs. last year but faced price pressure, indicating volume growth may continue but with cyclical price volatility.
- German subsidiary started sales in Q3 FY22 with INR 6.1 crores revenue; further growth depends on feed market prices and customer approvals.
- US subsidiary is expanding human nutrition portfolio to balance animal feed dependence, aiming for 45%-50% human nutrition share in the US market within three years.
- Premix plant in Kullu (Rs. 40 crores investment) underway to support basket expansion ahead of Saykha plant commissioning.
- Real estate monetization expected to fund Saykha CAPEX, facilitating manufacturing growth of nutraceutical products.
- Overall, growth drivers include new capacities, geographic expansion, and product diversification in human nutrition.
See what Fermenta Biotech management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no explicit mention of any current or planned new fundraising through debt or equity in the transcript.
- The company is focused on monetizing real estate assets, particularly through a structured joint development deal for its Thane land, rather than raising funds through equity or debt.
- Satish Varma mentions that monetization of real estate will play a large role in funding expansions such as the Saykha CAPEX.
- The management indicated no immediate plans or discussions about equity or debt fundraising; emphasis is on asset monetization and internal funding.
- They are also focused on completing ongoing merger processes before any major structural financial moves like a new listing on NSE.
See what Fermenta Biotech management said on order book — free account, 30 seconds.
Capex plans
Yes- The company is investing around Rs. 40 crores in a premix plant located in Kullu to expand its product basket, expected to be operational in 8 to 10 months.
- They plan further expansion through a larger Saykha plant once real estate monetization is sufficiently progressed.
- Real estate monetization, including the Thane land development deal, is intended to fund future CAPEX especially for the Saykha facility.
- The Saykha CAPEX has been delayed but is a key growth driver.
- Management is adopting a dynamic approach, utilizing existing capacities while preparing for Saykha's launch.
- No immediate involvement in construction or development—the company contributes land and receives developed carpet area in return.
- Other strategic moves include exploring value addition closer to European or American markets.
Track Fermenta Biotech — get its next earnings analysis in your feed
How does Fermenta Biotech rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Fermenta Biotech rank in Pharmaceuticals & Biotechnology?
Compare Fermenta Biotech against every Pharmaceuticals & Biotechnology company (Q3 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Fermenta Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem